IL1B and neoplasm: Furthermore, the reduction of IL-1β can be directly related to ROS reduction, also induced by treatment with ACS-AZ, since ROS can directly affect the tumor microenvironment by releasing inflammatory cytokines, among them IL-1β (Gu et al., 2018).